NCT02375022View on ClinicalTrials.gov

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Lung Cancer
Interventions
DRUG

Endostar and icotinib

Endostar and icotinib are used as combination therapy.

Trial Locations (1)

310000

RECRUITING

Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Beta Pharma, Inc.

INDUSTRY

lead

Zhejiang University

OTHER

NCT02375022 - Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations | Biotech Hunter | Biotech Hunter